Previous 10 | Next 10 |
LOUGHBOROUGH, March 15, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and ...
2023-03-09 18:17:45 ET Nemaura Medical ( NASDAQ: NMRD ) said Thursday on February 23, 2023, it was notified by Nasdaq that the company was not in compliance with a certain listing rule. Nemaura was not in compliance due to failure to timely file its form 10-Q for the fiscal qu...
LOUGHBOROUGH, March 09, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight re...
Nemaura Medical press release ( NASDAQ: NMRD ): Q3 GAAP EPS of -$0.07. Revenue of $0.03M (-83.3% Y/Y). Cash and cash equivalents at December 31, 2022 were approximately $7.3 million. For further details see: Nemaura Medical GAAP EPS of -$0.07, revenue of $0.03M
Loughborough, England, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and ...
Nemaura (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs. The company today announced that its CEO Dr. Faz Chowdhury will participate in a fireside chat at th...
Loughborough, England, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs, announces that CEO Dr. Faz Cho...
Nemaura Medical (NASDAQ: NMRD) is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R) and proBEAT(TM). sugarBEAT(R), a CE mark approved Class IIb medical device, is a non-invasive and fle...
The Wearable Medical Devices Market size is expected to be worth around USD 196.7 billion by 2030 valued at USD 21.7 billion in 2021 and growing at a CAGR of 28.3% during the forecast period from 2022 to 2030. This comprehensive analysis of the fastest-growing Wearable Medical...
Nemaura (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable sensors and supporting personalized lifestyle and weight reduction programs. The company today announced the close of its registered direct offering with two health care-focused...
News, Short Squeeze, Breakout and More Instantly...
Nemaura Medical Inc. Company Name:
NMRD Stock Symbol:
NASDAQ Market:
NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Maxim Group LLC, a full-service investment banking, securities and wealth management firm, and M-Vest, a digital community built for issuers, investors, and thought leaders, present the 2024 Healthcare IT Virtual Conference. The conference will take pla...
Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will imp...
Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel gr...